Welcome!

News Feed Item

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014

NEW YORK, April 24, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014

http://www.reportlinker.com/p02063647/Gastroesophageal-GE-Junction-Carcinomas-Global-Clinical-Trials-Review-H1-2014.html

Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014" provides data on the Gastroesophageal (GE) Junction Carcinomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastroesophageal (GE) Junction Carcinomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gastroesophageal (GE) Junction Carcinomas. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Introduction 7
Gastroesophageal (GE) Junction Carcinomas 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Unaccomplished Trials of Gastroesophageal (GE) Junction Carcinomas 26
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials 32
Prominent Drugs 34
Latest Clinical Trials News on Gastroesophageal (GE) Junction Carcinomas 35
May 16, 2012: Amgen Presents Results From Exploratory Biomarker Analysis Of Rilotumumab 35
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
AstraZeneca PLC 36
Clinical Trial Overview of AstraZeneca PLC 36
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
Amgen Inc. 38
Clinical Trial Overview of Amgen Inc. 38
Novartis AG 39
Clinical Trial Overview of Novartis AG 39
Bristol-Myers Squibb Company 40
Clinical Trial Overview of Bristol-Myers Squibb Company 40
Eli Lilly and Company 41
Clinical Trial Overview of Eli Lilly and Company 41
C. H. Boehringer Sohn AG & Co. KG 42
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 42
Dainippon Sumitomo Pharma Co., Ltd. 43
Clinical Trial Overview of Dainippon Sumitomo Pharma Co., Ltd. 43
Aphton Corporation (Inactive) 44
Clinical Trial Overview of Aphton Corporation (Inactive) 44
Amgen research GmbH 45
Clinical Trial Overview of Amgen research GmbH 45
Clinical Trial Overview of Top Institutes / Government 46
National Cancer Institute 46
Clinical Trial Overview of National Cancer Institute 46
North Central Cancer Treatment Group 48
Clinical Trial Overview of North Central Cancer Treatment Group 48
Case Comprehensive Cancer Center 49
Clinical Trial Overview of Case Comprehensive Cancer Center 49
Stanford University 50
Clinical Trial Overview of Stanford University 50
Sidney Kimmel Comprehensive Cancer Center 51
Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center 51
Memorial Sloan Kettering Cancer Center 52
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 52
Southwest Oncology Group 53
Clinical Trial Overview of Southwest Oncology Group 53
University of Pittsburgh 54
Clinical Trial Overview of University of Pittsburgh 54
Fox Chase Cancer Center 55
Clinical Trial Overview of Fox Chase Cancer Center 55
The University of Texas M. D. Anderson Cancer Center 56
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 56
Five Key Clinical Profiles 57
Appendix 104
Abbreviations 104
Definitions 104
Research Methodology 105
Secondary Research 105
About GlobalData 106
Contact Us 106
Disclaimer 106
Source 107

List of Tables

Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Region, 2014* 8
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 11
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 12
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, North America, Top Countries, 2014* 13
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 14
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 15
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Phase, 2014* 22
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 23
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Suspended Clinical Trials, 2014* 26
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Gastroesophageal (GE) Junction Carcinomas Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 30
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 33
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 36
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 37
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 38
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 39
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 40
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 41
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 42
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Dainippon Sumitomo Pharma Co., Ltd., 2014* 43
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Aphton Corporation (Inactive), 2014* 44
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen research GmbH, 2014* 45
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 46
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by North Central Cancer Treatment Group, 2014* 48
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 49
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 50
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2014* 51
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 52
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Southwest Oncology Group, 2014* 53
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pittsburgh, 2014* 54
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by Fox Chase Cancer Center, 2014* 55
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 56

List of Figures
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Region (%), 2014* 8
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 9
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 10
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 11
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 12
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 13
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 14
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 15
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, G7 Countries (%), 2014* 16
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 17
Gastroesophageal (GE) Junction Carcinomas Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 18
Proportion of Gastroesophageal (GE) Junction Carcinomas to Oncology Clinical Trials, E7 Countries (%), 2014* 19
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 20
Gastroesophageal (GE) Junction Carcinomas Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 21
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Phase (%), 2014* 22
Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 23
Gastroesophageal (GE) Junction Carcinomas Therapeutics, Global, Clinical Trials by Trial Status, 2014* 24
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, by End Point Status, 2014* 25
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Gastroesophageal (GE) Junction Carcinomas Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 30
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Gastroesophageal (GE) Junction Carcinomas Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 34
GlobalData Methodology 105

To order this report: Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02063647/Gastroesophageal-GE-Junction-Carcinomas-Global-Clinical-Trials-Review-H1-2014.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor – all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
Join IBM November 2 at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how to go beyond multi-speed it to bring agility to traditional enterprise applications. Technology innovation is the driving force behind modern business and enterprises must respond by increasing the speed and efficiency of software delivery. The challenge is that existing enterprise applications are expensive to develop and difficult to modernize. This often results in what Gartner calls ...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
“DevOps is really about the business. The business is under pressure today, competitively in the marketplace to respond to the expectations of the customer. The business is driving IT and the problem is that IT isn't responding fast enough," explained Mark Levy, Senior Product Marketing Manager at Serena Software, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events announced today that CollabNet, a global leader in enterprise software development, release automation and DevOps solutions, will be a Bronze Sponsor of SYS-CON's 20th International Cloud Expo®, taking place from June 6-8, 2017, at the Javits Center in New York City, NY. CollabNet offers a broad range of solutions with the mission of helping modern organizations deliver quality software at speed. The company’s latest innovation, the DevOps Lifecycle Manager (DLM), supports Value S...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
Translating agile methodology into real-world best practices within the modern software factory has driven widespread DevOps adoption, yet much work remains to expand workflows and tooling across the enterprise. As models evolve from pockets of experimentation into wholescale organizational reinvention, practitioners find themselves challenged to incorporate the culture and architecture necessary to support DevOps at scale. In his session at @DevOpsSummit at 20th Cloud Expo, Anand Akela, Senior...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the USA and Europe, we work with a variety of customers from emerging startups to Fortune 1000 companies.
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.